<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02545517</url>
  </required_header>
  <id_info>
    <org_study_id>205214</org_study_id>
    <secondary_id>2015-000382-31</secondary_id>
    <secondary_id>v49_23E1</secondary_id>
    <nct_id>NCT02545517</nct_id>
  </id_info>
  <brief_title>A Phase 3 Clinical Trial to Evaluate Long-term Immunogenicity and Boostability of Purified Chick-Embryo Cell Rabies Vaccine in Adults Following Primary Series of Pre/Exposure Prophylaxis.</brief_title>
  <official_title>A Phase 3, Open-label, Multicenter Study to Evaluate Long-term Immunogenicity and Boostability of Immune Responses in Adults Who Received Different Primary Vaccination Regimens of Pre-exposure Prophylaxis With Purified Chick-Embryo Cell Rabies Vaccine Administered Concomitantly or Separately From a Japanese Encephalitis Vaccine.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the long-term (up to approx.10 years) persistence and to
      assess the boostability of immune responses in subjects who received a primary series of
      accelerated or conventional rabies PrEP IM regimen.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 1, 2015</start_date>
  <completion_date type="Anticipated">December 3, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 3, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary immunogenicity endpoints will be based on the concentrations at Year 3, following a primary series of accelerated or conventional rabies PrEP IM regimen, as measured by rapid fluorescent focus inhibition test (RFFIT).</measure>
    <time_frame>Year 3</time_frame>
    <description>*RVNA : Rabies Virus Neutralizing Antibodies. RFFIT : Rapid Fluorescent Focus Inhibition Test.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The primary immunogenicity endpoints will be based on the concentrations at Year 4 following a primary series of accelerated or conventional rabies PrEP IM regimen, as measured by rapid fluorescent focus inhibition test (RFFIT).</measure>
    <time_frame>Year 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The primary immunogenicity endpoints will be based on the concentrations at Year 5 following a primary series of accelerated or conventional rabies PrEP IM regimen, as measured by rapid fluorescent focus inhibition test (RFFIT).</measure>
    <time_frame>Year 5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The primary immunogenicity endpoints will be based on the concentrations at Year 6 following a primary series of accelerated or conventional rabies PrEP IM regimen, as measured by rapid fluorescent focus inhibition test (RFFIT).</measure>
    <time_frame>Year 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The primary immunogenicity endpoints will be based on the concentrations at Year 7 following a primary series of accelerated or conventional rabies PrEP IM regimen, as measured by rapid fluorescent focus inhibition test (RFFIT).</measure>
    <time_frame>Year 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The primary immunogenicity endpoints will be based on the concentrations at Year 8 following a primary series of accelerated or conventional rabies PrEP IM regimen, as measured by rapid fluorescent focus inhibition test (RFFIT).</measure>
    <time_frame>Year 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The primary immunogenicity endpoints will be based on the concentrations at Year 9 following a primary series of accelerated or conventional rabies PrEP IM regimen, as measured by rapid fluorescent focus inhibition test (RFFIT).</measure>
    <time_frame>Year 9</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The primary immunogenicity endpoints will be based on the concentrations at Year 10 following a primary series of accelerated or conventional rabies PrEP IM regimen, as measured by rapid fluorescent focus inhibition test (RFFIT).</measure>
    <time_frame>Year 10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to first RVNA concentrations &lt; 0.5 IU/mL.</measure>
    <time_frame>All study duration (outcome measure is a time so we cannot specify the particular timepoint)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Concentrations (GMCs) for subjects receiving the booster dose at 7 days after the booster dose</measure>
    <time_frame>7 days after the booster dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Concentrations (GMCs) for subjects receiving the booster dose.</measure>
    <time_frame>before the booster dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Ratios (GMRs) for subjects receiving the booster dose, as measured by antibody concentration at 7 days after the booster dose vs. antibody concentration before the booster dose.</measure>
    <time_frame>7 days after the booster dose vs. antibody concentration before the booster dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentages of subjects with RVNA concentrations ≥ 0.5 IU/mL, as measured by RFFIT assay at 7 days after the booster dose and at subsequent Scheduled Clinic Visits.</measure>
    <time_frame>Year 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentages of subjects with RVNA concentrations ≥ 0.5 IU/mL, as measured by RFFIT assay at 7 days after the booster dose and at subsequent Scheduled Clinic Visits.</measure>
    <time_frame>Year 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentages of subjects with RVNA concentrations ≥ 0.5 IU/mL, as measured by RFFIT assay at 7 days after the booster dose and at subsequent Scheduled Clinic Visits.</measure>
    <time_frame>Year 5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentages of subjects with RVNA concentrations ≥ 0.5 IU/mL, as measured by RFFIT assay at 7 days after the booster dose and at subsequent Scheduled Clinic Visits.</measure>
    <time_frame>Year 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentages of subjects with RVNA concentrations ≥ 0.5 IU/mL, as measured by RFFIT assay at 7 days after the booster dose and at subsequent Scheduled Clinic Visits.</measure>
    <time_frame>Year 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentages of subjects with RVNA concentrations ≥ 0.5 IU/mL, as measured by RFFIT assay at 7 days after the booster dose and at subsequent Scheduled Clinic Visits.</measure>
    <time_frame>Year 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentages of subjects with RVNA concentrations ≥ 0.5 IU/mL, as measured by RFFIT assay at 7 days after the booster dose and at subsequent Scheduled Clinic Visits.</measure>
    <time_frame>Year 9</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentages of subjects with RVNA concentrations ≥ 0.5 IU/mL, as measured by RFFIT assay at 7 days after the booster dose and at subsequent Scheduled Clinic Visits.</measure>
    <time_frame>Year 10</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Antibody Concentrations (GMCs) at Year 3.</measure>
    <time_frame>Year 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Antibody Concentrations (GMCs) at Year 4.</measure>
    <time_frame>Year 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Antibody Concentrations (GMCs) at Year 5.</measure>
    <time_frame>Year 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Antibody Concentrations (GMCs) at Year 6.</measure>
    <time_frame>Year 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Antibody Concentrations (GMCs) at Year 7.</measure>
    <time_frame>Year 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Antibody Concentrations (GMCs) at Year 8.</measure>
    <time_frame>Year 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Antibody Concentrations (GMCs) at Year 9.</measure>
    <time_frame>Year 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Antibody Concentrations (GMCs) at Year 10.</measure>
    <time_frame>Year 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reverse Cumulative Distribution Plots (RCDPs) for subjects with RVNA concentrations ≥ 0.5 IU/mL at Year 3.</measure>
    <time_frame>Year 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reverse Cumulative Distribution Plots (RCDPs) for subjects with RVNA concentrations ≥ 0.5 IU/mL at Year 4.</measure>
    <time_frame>Year 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reverse Cumulative Distribution Plots (RCDPs) for subjects with RVNA concentrations ≥ 0.5 IU/mL at Year 5.</measure>
    <time_frame>Year 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reverse Cumulative Distribution Plots (RCDPs) for subjects with RVNA concentrations ≥ 0.5 IU/mL at Year 6.</measure>
    <time_frame>Year 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reverse Cumulative Distribution Plots (RCDPs) for subjects with RVNA concentrations ≥ 0.5 IU/mL at Year 7.</measure>
    <time_frame>Year 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reverse Cumulative Distribution Plots (RCDPs) for subjects with RVNA concentrations ≥ 0.5 IU/mL at Year 8.</measure>
    <time_frame>Year 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reverse Cumulative Distribution Plots (RCDPs) for subjects with RVNA concentrations ≥ 0.5 IU/mL at Year 9.</measure>
    <time_frame>Year 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reverse Cumulative Distribution Plots (RCDPs) for subjects with RVNA concentrations ≥ 0.5 IU/mL at Year 10.</measure>
    <time_frame>Year 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of subjects with RVNA concentrations ≥ 0.5 IU/mL, as measured by RFFIT assay at Year 3.</measure>
    <time_frame>Year 3.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of subjects with RVNA concentrations ≥ 0.5 IU/mL, as measured by RFFIT assay at Year 4.</measure>
    <time_frame>Year 4.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of subjects with RVNA concentrations ≥ 0.5 IU/mL, as measured by RFFIT assay at Year 5.</measure>
    <time_frame>Year 5.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of subjects with RVNA concentrations ≥ 0.5 IU/mL, as measured by RFFIT assay at Year 6.</measure>
    <time_frame>Year 6.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of subjects with RVNA concentrations ≥ 0.5 IU/mL, as measured by RFFIT assay at Year 7.</measure>
    <time_frame>Year 7.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of subjects with RVNA concentrations ≥ 0.5 IU/mL, as measured by RFFIT assay at Year 8.</measure>
    <time_frame>Year 8.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of subjects with RVNA concentrations ≥ 0.5 IU/mL, as measured by RFFIT assay at Year 9.</measure>
    <time_frame>Year 9.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of subjects with RVNA concentrations ≥ 0.5 IU/mL, as measured by RFFIT assay at Year 10.</measure>
    <time_frame>Year 10.</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Number and percentages of Serious Adverse Events (SAEs) for subjects receiving PCEC rabies booster vaccination, will be collected and summarized starting from the booster administration and until the day of next scheduled clinic visit</measure>
    <time_frame>Year 3</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number and percentages of Serious Adverse Events (SAEs) for subjects receiving PCEC rabies booster vaccination, will be collected and summarized starting from the booster administration and until the day of next scheduled clinic visit</measure>
    <time_frame>Year 4</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number and percentages of Serious Adverse Events (SAEs) for subjects receiving PCEC rabies booster vaccination, will be collected and summarized starting from the booster administration and until the day of next scheduled clinic visit</measure>
    <time_frame>Year 5</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number and percentages of Serious Adverse Events (SAEs) for subjects receiving PCEC rabies booster vaccination, will be collected and summarized starting from the booster administration and until the day of next scheduled clinic visit</measure>
    <time_frame>Year 6</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number and percentages of Serious Adverse Events (SAEs) for subjects receiving PCEC rabies booster vaccination, will be collected and summarized starting from the booster administration and until the day of next scheduled clinic visit</measure>
    <time_frame>Year 7</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number and percentages of Serious Adverse Events (SAEs) for subjects receiving PCEC rabies booster vaccination, will be collected and summarized starting from the booster administration and until the day of next scheduled clinic visit</measure>
    <time_frame>Year 8</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number and percentages of Serious Adverse Events (SAEs) for subjects receiving PCEC rabies booster vaccination, will be collected and summarized starting from the booster administration and until the day of next scheduled clinic visit</measure>
    <time_frame>Year 9</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number and percentages of Serious Adverse Events (SAEs) for subjects receiving PCEC rabies booster vaccination, will be collected and summarized starting from the booster administration and until the day of next scheduled clinic visit</measure>
    <time_frame>Year 10</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">578</enrollment>
  <condition>Rabies</condition>
  <arm_group>
    <arm_group_label>Booster dose single group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who received a primary series of accelerated or conventional rabies PrEP IM regimen in the parent study, will receive a booster dose based on their individual antibody concentrations measured over time.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Purified Chick-Embryo Cell Rabies Vaccine</intervention_name>
    <description>1 booster dose of 1.0 mL of Purified Chick-Embryo Cell Rabies Vaccine intramuscular (IM)</description>
    <arm_group_label>Booster dose single group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All individuals who were randomized to a Rabies primary series vaccination for
             pre-exposure prophylaxis (PrEP), received the full PrEP regimen and completed the
             parent trial following study protocol.

        Exclusion Criteria:

          -  Completed the parent study without receiving the full 3 rabies vaccine doses following
             the assigned pre-exposure prophylaxis regimen.

          -  History of exposure to suspected or confirmed rabid animal.

          -  Receipt of rabies immunoglobulins, rabies post exposure prophylaxis following
             completion of the parent study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>80802</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rostock</city>
        <state>Mecklenburg-Vorpommern</state>
        <zip>18057</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20359</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Zuerich</city>
        <zip>8001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2015</study_first_submitted>
  <study_first_submitted_qc>September 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2015</study_first_posted>
  <last_update_submitted>February 15, 2018</last_update_submitted>
  <last_update_submitted_qc>February 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rabies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

